Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 14/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.49 |
| ▸ | CDK4 | P11802 | 5/20 | 0.49 |
| ▸ | CCND3 | P30281 | 5/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.45 |
| ▸ | CDK2 | P24941 | 17/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22976994 | 1.00 | CCND1 (0.49) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22976959 | 0.95 | CCND1 (0.47) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL29821221 | 0.95 | CCND1 (0.47) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22977229 | 0.91 | CDK6 (0.47) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22977060 | 0.91 | CDK6 (0.47) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22977136 | 0.90 | CCNE1 (0.57) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22977112 | 0.87 | CCND1 (0.46) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22976933 | 0.87 | CCNE1 (0.46) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22977502 | 0.87 | CCND1 (0.46) | CCND1CDK6CDK4CCND3CCNE1 | |
| SCHEMBL22977360 | 0.87 | CCND1 (0.46) | CCND1CDK6CDK4CCND3CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | claimed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | claimed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | claimed |
| EP-4013750-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2021030537-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-02-18 | — | — | WO | claimed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | claimed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2025-05-27 | — | — | US | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2021030537-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312331-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | CCND1 54/4885CDK6 12/4885CDK4 2/4885 |
| US-11427567-B2 | Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK4, CDK2AP2 | CCND1 54/4885CDK6 12/4885CDK4 2/4885 |
| US-20210047294-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CCND1 54/4885CDK6 12/4885CDK4 2/4885 |
| US-20230024173-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CCND1 54/4885CDK6 12/4885CDK4 2/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | CCND1 54/4885CDK6 12/4885CDK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.